Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04508023 · ClinicalTrials.gov registry record · Phase 3
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
A Phase 3 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,284
- Enrollment target
NCT04508023 is a Phase 3 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 1,284 participants.
The verdict
NCT04508023, a Phase 3 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,284 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether rivaroxaban reduces the risk of a composite endpoint of major venous and arterial thrombotic events, all-cause hospitalization, and all-cause mortality compared with placebo in outpatients with acute, symptomatic Coronavirus Disease 2019 (COVID-19) Infection.
Interventions
- OTHER Placebo
- OTHER Standard of Care (SOC)
- DRUG Rivaroxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,284 participants |
| Start Date | 2020-08-13 |
| Est. Completion | 2022-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04508023
The ClinicalTrials.gov registry entry for NCT04508023 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,284 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04508023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04508023 about?
NCT04508023 is a clinical study titled "A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection". The purpose of this study is to evaluate whether rivaroxaban reduces the risk of a composite endpoint of major venous and arterial thrombotic events, all-cause hospitalization, and all-cause mortality compared with placebo in outpatients with acute, symptomatic Coronavirus Disease 2019 (COVID-19) In...
What is the current status of trial NCT04508023?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,284 participants. The study started on 2020-08-13. Estimated completion is 2022-06-01.
What interventions are being tested in trial NCT04508023?
The interventions under investigation include: Placebo (OTHER), Standard of Care (SOC) (OTHER), Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT04508023?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.